With a broad experience in the pharmaceutical industry spanning over more than 25 years, Dermot joined STEM as CEO in November 2021. As CEO, Dermot is responsible for driving growth and innovation within STEM.
Prior to joining STEM Dermot spent 5 years at Novartis in the Clinical Development arena, first leading a major transformation in clinical data operations and then leading the broader clinical technology and innovation function. In this role, Dermot had responsibility for the support, oversight and evolution of Novartis’ end to end clinical technology platform and for driving digitization and innovation in the execution of clinical trials.
